Search

everythinglearnresearchcommunity

for

Search:↓

Men who start balding at age 20 may have a higher chance of getting aggressive prostate cancer.

KGF and its receptor are found in enlarged prostate tissue and KGF strongly increases cell growth.

Birth control pills increase certain receptor activities in female gerbil prostate glands and can lead to prostate changes.

Enzalutamide, a prostate cancer drug, may help prevent COVID-19 by blocking the virus from entering lung cells.

New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.

The IPP index is linked to storage symptoms and leftover urine, and may help manage urinary tract symptoms.

IGRT resulted in lower acute toxicity for stage III prostate cancer patients.

Cone beam computed tomography can allow for smaller safety margins around the target area in prostate cancer radiation treatment if used for ongoing treatment checks.

The conclusion is that more hair loss (androgenetic alopecia) is linked to larger prostate size, suggesting hair loss could be an early sign of benign prostatic hyperplasia.

Hormone therapy might be a proactive alternative to watchful waiting for early-stage prostate cancer, potentially improving survival without aggressive treatment downsides.

The new method found new shared genetic areas linked to both Type 2 Diabetes and Prostate Cancer.

Treatment with 5α-reductase inhibitors is linked to a delay in prostate cancer diagnosis and may affect survival rates.

Anti-androgen therapy may boost immunity but increases injection site pain in vaccinated patients.

The document concludes that the 5 alpha-reductase enzymes are important in steroid metabolism and related to various human diseases, with inhibitors used to treat conditions like male pattern baldness and prostate issues.

Finasteride treats enlarged prostate and may help with baldness, but effects on sexual function and male fetuses are unclear.

Dihydrotestosterone gel improved well-being and sexual function in older men without negatively affecting prostate health.

Scientists made the first metal-based compounds from a nonsteroidal antiandrogen drug, which showed potential in fighting both hormone-dependent and independent prostate cancer cells.

Long-term testosterone therapy can cause hormone suppression, affect prostate and heart health, and alter physical characteristics, but does not increase prostate cancer risk and needs more research for full risk assessment.

The length of the CAG repeat in the androgen receptor gene affects the risk and progression of prostate cancer, BPH, infertility, and undermasculinized genitalia.

Certain drugs that block specific enzymes can help treat prostate diseases.

Antiandrogens may help treat conditions like excessive hair growth, prostate tumors, male baldness, and acne by blocking male hormone effects.

Testosterone can build muscle and bone without enlarging the prostate when a specific enzyme is blocked.

Finasteride reduces PSA levels, terazosin doesn't affect them, and tracking prostate cancer in patients taking finasteride could be difficult.

Different drugs for prostate-related urinary symptoms work but have various side effects, and treatment should be tailored to the individual.

Using finasteride with TIP extends time off period for prostate cancer patients.

Flutamide combined with an LHRH agonist effectively inhibits prostate growth, suggesting it could treat prostate cancer.

Higher testosterone levels can increase the risk of certain diseases like type 2 diabetes in women and prostate cancer in men, but can also protect against autoimmune diseases and hair loss. It also affects body fat and bone density.

Early onset baldness in men may indicate a condition similar to PCOS, linked to heart disease, diabetes, and prostate issues.

Early hair loss may indicate prostate issues.

Dutasteride effectively treats benign prostatic hyperplasia but isn't approved for preventing prostate cancer.